Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18752290 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | June 2024 | January 2025 | Allow | 7 | 0 | 1 | No | No |
| 18640905 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | April 2024 | March 2025 | Allow | 11 | 1 | 0 | No | No |
| 18317177 | OLIGONUCLEOTIDE AND USE THEREOF AGAINST HEPATITIS B VIRUS AND HEPATITIS D VIRUS | March 2024 | December 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18582279 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | February 2024 | February 2025 | Allow | 12 | 2 | 0 | No | No |
| 18523746 | Compounds and Methods for Reducing LRRK2 Expression | November 2023 | August 2024 | Allow | 9 | 0 | 0 | No | No |
| 18523743 | DIAGNOSTIC KIT FOR METASTASIS AND INVASION OF BREAST CANCER AND USE OF shRNA MOLECULE FOR SILENCING EXPRESSION OF HUMAN LINC01614 | November 2023 | March 2025 | Allow | 15 | 2 | 0 | No | No |
| 18507175 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | November 2023 | May 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18484291 | PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | October 2023 | May 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18346686 | NUCLEIC ACIDS ENCODING CRISPR-ASSOCIATED PROTEINS AND USES THEREOF | July 2023 | March 2025 | Allow | 20 | 0 | 1 | No | No |
| 18345407 | THERAPEUTIC OLIGONUCLEOTIDES | June 2023 | April 2025 | Allow | 21 | 1 | 1 | No | No |
| 18333007 | Selective Antisense Compounds and Uses Thereof | June 2023 | March 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18314258 | RNA-Editing Oligonucleotides and Uses Thereof | May 2023 | August 2024 | Allow | 15 | 2 | 1 | No | No |
| 18130278 | METHODS AND COMPOSITIONS FOR TREATING A PREMATURE STOP CODON-MEDIATED DISORDER | April 2023 | December 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18178206 | ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS | March 2023 | March 2025 | Allow | 24 | 2 | 1 | No | No |
| 18146840 | Adeno-Associated Virus Vector Delivery of Muscle Specific Micro-Dystrophin to Treat Muscular Dystrophy | December 2022 | April 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18059606 | REGULATION OF GENE EXPRESSION VIA APTAMER-MEDIATED CONTROL OF SELF-CLEAVING RIBOZYMES | November 2022 | March 2025 | Allow | 28 | 1 | 1 | No | No |
| 18054813 | DNA COMPOSITIONS AND RELATED METHODS | November 2022 | January 2025 | Allow | 26 | 4 | 1 | Yes | No |
| 17960090 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | October 2022 | March 2025 | Abandon | 29 | 1 | 1 | No | No |
| 17818858 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | August 2022 | November 2024 | Allow | 27 | 2 | 1 | No | No |
| 17817874 | RNA-Editing Oligonucleotides and Uses Thereof | August 2022 | May 2025 | Allow | 33 | 1 | 1 | No | No |
| 17811961 | siRNA based on RNA sequence of SARS-CoV-2 and use thereof | July 2022 | September 2024 | Allow | 26 | 2 | 1 | No | No |
| 17829801 | Treatment Of Cerebrovascular Disease With Neurogenic Locus Notch Homolog Protein 3 (NOTCH3) Agents | June 2022 | September 2024 | Allow | 27 | 4 | 1 | No | No |
| 17732757 | TREATMENT METHODS FOR MUSCULAR DYSTROPHY | April 2022 | January 2025 | Allow | 32 | 1 | 0 | No | No |
| 17680940 | Treatment Of Liver Disease With Mitochondrial Glycerol-3-Phosphate Acyltransferase (GPAM) Inhibitors | February 2022 | September 2024 | Allow | 31 | 3 | 1 | No | No |
| 17570714 | MICRORNAS FOR CARDIAC REGENERATION THROUGH INDUCTION OF CARDIAC MYOCYTE PROLIFERATION | January 2022 | April 2025 | Allow | 39 | 3 | 1 | No | No |
| 17623569 | NOVEL COMPOUND AND APPLICATION THEREOF | December 2021 | April 2025 | Allow | 39 | 2 | 1 | Yes | No |
| 17544984 | SERUM AMYLOID P COMPONENT (APCS) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | December 2021 | December 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17471719 | GAPMER ANTISENSE OLIGONUCLEOTIDES TARGETING SARS-COV-2 FOR TREATING COVID 19 | September 2021 | July 2024 | Allow | 34 | 3 | 1 | No | No |
| 17437507 | COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION | September 2021 | November 2024 | Allow | 38 | 0 | 0 | No | No |
| 17437123 | NON-VIRAL DNA VECTORS AND USES THEREOF FOR EXPRESSING FVIII THERAPEUTICS | September 2021 | February 2025 | Allow | 41 | 0 | 1 | No | No |
| 17372173 | MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS | July 2021 | March 2024 | Allow | 33 | 5 | 0 | No | No |
| 17371935 | 5'-CAP COMPOUNDS AND THEIR USES IN STABILIZING RNA, EXPRESSING PROTEINS AND IN THERAPY | July 2021 | December 2024 | Abandon | 41 | 6 | 1 | Yes | Yes |
| 17420460 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | July 2021 | August 2024 | Allow | 38 | 0 | 0 | No | No |
| 17339366 | P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION | June 2021 | January 2025 | Allow | 44 | 4 | 0 | No | No |
| 17319391 | CCR7 APTAMERS AND USES THEREOF | May 2021 | August 2024 | Allow | 40 | 2 | 0 | No | No |
| 17314962 | SYSTEMS AND METHODS FOR USE OF ADENOSINE TRIPHOSPHATE (ATP) TO RELIEVE SYMPTOMS OF COVID-19 AND RELATED INFECTIONS | May 2021 | March 2025 | Allow | 46 | 3 | 0 | Yes | No |
| 17239461 | DISEASE STRATIFICATION OF LIVER DISEASE AND RELATED METHODS | April 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17211622 | NUCLEIC ACIDS FOR CELL RECOGNITION AND INTEGRATION | March 2021 | June 2025 | Allow | 51 | 1 | 1 | No | No |
| 17268590 | Inducing Proliferation of Cardiomyocytes and Therapeutic Uses Related Thereto | February 2021 | January 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17175156 | OLIGONUCLEOTIDES TARGETING FRATAXIN AND RELATED METHODS | February 2021 | January 2025 | Allow | 47 | 3 | 1 | Yes | Yes |
| 17258544 | METHODS FOR TARGETING PAIN DIRECTED AT METABOLIC PATHWAYS | January 2021 | July 2024 | Allow | 42 | 0 | 1 | No | No |
| 16973464 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | December 2020 | May 2025 | Abandon | 53 | 1 | 1 | No | No |
| 17048236 | GENE THERAPY FOR DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS INCLUDING MITOCHONDRIAL DNA DEPLETION SYNDROMES | October 2020 | June 2025 | Allow | 56 | 2 | 1 | No | No |
| 17023003 | COMPOSITION FOR TEMPERATURE SENSORS INCLUDING GRAPHENE OXIDE, DNAZYME AND PNA AND TEMPERATURE SENSING METHOD USING THE SAME | September 2020 | September 2024 | Allow | 48 | 1 | 1 | No | No |
| 16980300 | 5'-CAP-TRINUCLEOTIDE- OR HIGHER OLIGONUCLEOTIDE COMPOUNDS AND THEIR USE IN STABILIZING RNA, EXPRESSING PROTEINS IN THERAPY | September 2020 | January 2025 | Allow | 52 | 3 | 1 | Yes | No |
| 16963583 | METHOD OF INTRODUCING AN mRNA MOLECULE INTO A CELL | July 2020 | November 2024 | Allow | 52 | 2 | 1 | Yes | No |
| 16896811 | METHODS OF IMPROVING ADENO-ASSOCIATED VIRAL TRANSDUCTION | June 2020 | September 2024 | Allow | 52 | 5 | 0 | Yes | No |
| 16626395 | ANTISENSE OLIGONUCLEOTIDES FOR MODULATING THE FUNCTION OF A T CELL | December 2019 | August 2024 | Allow | 56 | 4 | 1 | No | No |
| 15974941 | TRANSCRIPTOMIC INDEX FOR CHARACTERIZING THE CELLULAR REPAIR RESPONSE AFTER SOFT TISSUE INJURY IN DIARTHRODIAL JOINTS | May 2018 | January 2025 | Allow | 60 | 5 | 0 | No | No |
| 15893532 | FUNCTIONAL LIGANDS TO TARGET MOLECULES | February 2018 | April 2019 | Allow | 15 | 1 | 1 | No | No |
| 15563313 | NUCLEIC ACID APTAMERS BINDING TO VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS | September 2017 | August 2018 | Allow | 10 | 0 | 1 | No | No |
| 15642581 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS | July 2017 | July 2019 | Allow | 24 | 1 | 0 | No | No |
| 15625945 | MiRNA and its Diagnostic and Therapeutic Uses in Diseases or Conditions Associated with Melanoma, or in Diseases or Conditions Associated with Activated BRAF Pathway | June 2017 | October 2019 | Allow | 28 | 3 | 0 | No | No |
| 15501097 | METHOD FOR DIAGNOSING FIBROMYALGIA USING MICRORNAS | February 2017 | August 2019 | Allow | 30 | 2 | 0 | Yes | No |
| 14701998 | TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A SIRTUIN (SIRT) | May 2015 | September 2019 | Allow | 53 | 8 | 1 | No | No |
| 13636910 | CELL GROWTH INHIBITOR AND SCREENING METHOD THEREOF | March 2013 | March 2014 | Allow | 25 | 1 | 1 | No | No |
| 13578023 | APTAMER TO FGF2 AND USE THEREOF | October 2012 | February 2014 | Allow | 19 | 1 | 1 | No | No |
| 13502154 | APTAMER CAPABLE OF BINDING TO VIRAL HEMORRHAGIC SEPTICEMIA VIRUS | June 2012 | August 2013 | Allow | 16 | 1 | 1 | No | No |
| 13470233 | DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC USES OF LONG NON-CODING RNAS FOR CANCER AND REGENERATIVE MEDICINE | May 2012 | August 2013 | Allow | 15 | 0 | 2 | Yes | No |
| 13501892 | EXON SKIPPING THERAPY FOR DYSFERLINOPATHIES | May 2012 | August 2013 | Allow | 16 | 1 | 0 | No | No |
| 13414084 | MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (MIR-155) LINKS INFLAMMATION AND CANCER | March 2012 | November 2013 | Allow | 20 | 2 | 0 | Yes | No |
| 13281810 | Baculovirus-Mediated Transgene Expression in Both Mammalian and Insect Cells | October 2011 | July 2013 | Allow | 21 | 1 | 1 | No | No |
| 13199484 | METHODS AND COMPOSITIONS OF NUCLEIC ACID LIGANDS FOR DETECTION OF CLINICAL ANALYTES RELATED TO HUMAN HEALTH | August 2011 | October 2013 | Allow | 25 | 2 | 1 | No | No |
| 13120650 | APTAMER FOR NGF AND USE THEREOF | June 2011 | August 2018 | Allow | 60 | 9 | 1 | Yes | No |
| 13099171 | Inhibition of Apoptosis-Specific eIF-5A(elF-5A1") with Antisense Oligonucleotides and siRNA as Anti-Inflammatory Therapeutics | May 2011 | January 2014 | Allow | 33 | 2 | 1 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner POLIAKOVA-GEORGAN, EKATERINA.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner POLIAKOVA-GEORGAN, EKATERINA works in Art Unit 1637 and has examined 62 patent applications in our dataset. With an allowance rate of 82.3%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 31 months.
Examiner POLIAKOVA-GEORGAN, EKATERINA's allowance rate of 82.3% places them in the 48% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by POLIAKOVA-GEORGAN, EKATERINA receive 1.97 office actions before reaching final disposition. This places the examiner in the 64% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by POLIAKOVA-GEORGAN, EKATERINA is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +12.7% benefit to allowance rate for applications examined by POLIAKOVA-GEORGAN, EKATERINA. This interview benefit is in the 53% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 24.6% of applications are subsequently allowed. This success rate is in the 27% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 43.8% of cases where such amendments are filed. This entry rate is in the 60% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 18.2% are granted (fully or in part). This grant rate is in the 9% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 1.6% of allowed cases (in the 74% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.